VERTEX PHARMACEUTICALS INC / MA Insider Trading for October 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for October 2019.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | M | 155.57 | 3,057 | 475,577 | 5,096 | |
Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | M | 155.57 | 3,057 | 475,577 | 5,096 | |
Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 199.00 | 3,057 | 608,343 | 13,098 | 16.2 K to 13.1 K (-18.92 %) |
Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 199.00 | 3,057 | 608,343 | 13,098 | 16.2 K to 13.1 K (-18.92 %) |
Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Buy | M | 155.57 | 3,057 | 475,577 | 16,155 | 13.1 K to 16.2 K (+23.34 %) |
Oct 31 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Buy | M | 155.57 | 3,057 | 475,577 | 16,155 | 13.1 K to 16.2 K (+23.34 %) |
Oct 29 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Option Exercise | M | 91.05 | 4,311 | 392,517 | 4,311 | |
Oct 29 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 195.01 | 4,311 | 840,688 | 33,416 | 37.7 K to 33.4 K (-11.43 %) |
Oct 29 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Buy | M | 91.05 | 4,311 | 392,517 | 37,727 | 33.4 K to 37.7 K (+12.90 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Option Exercise | M | 86.52 | 3,883 | 335,957 | 11,650 | |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Sell | S | 190.27 | 3,883 | 738,818 | 33,416 | 37.3 K to 33.4 K (-10.41 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, Chief Patient ... | Buy | M | 86.52 | 3,883 | 335,957 | 37,299 | 33.4 K to 37.3 K (+11.62 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | MCGLYNN MARGARET G | Director | Option Exercise | M | 72.14 | 20,000 | 1,442,800 | 0 | |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | MCGLYNN MARGARET G | Director | Sell | S | 190.00 | 20,000 | 3,800,000 | 4,124 | 24.1 K to 4.1 K (-82.90 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | MCGLYNN MARGARET G | Director | Buy | M | 72.14 | 20,000 | 1,442,800 | 24,124 | 4.1 K to 24.1 K (+484.97 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | M | 131.89 | 35,411 | 4,670,357 | 71,089 | |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | M | 109.14 | 72,420 | 7,903,919 | 140,580 | |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 190.00 | 35,411 | 6,728,090 | 106,287 | 141.7 K to 106.3 K (-24.99 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Buy | M | 131.89 | 35,411 | 4,670,357 | 141,698 | 106.3 K to 141.7 K (+33.32 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 190.00 | 72,420 | 13,759,800 | 106,287 | 178.7 K to 106.3 K (-40.52 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Buy | M | 109.14 | 72,420 | 7,903,919 | 178,707 | 106.3 K to 178.7 K (+68.14 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 189.00 | 638 | 120,582 | 13,098 | 13.7 K to 13.1 K (-4.64 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 155.57 | 3,669 | 570,786 | 12,229 | |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 194.37 | 3,669 | 713,144 | 31,553 | 35.2 K to 31.6 K (-10.42 %) |
Oct 24 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 155.57 | 3,669 | 570,786 | 35,222 | 31.6 K to 35.2 K (+11.63 %) |
Oct 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 122.45 | 4,250 | 520,413 | 4,250 | |
Oct 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 177.80 | 4,250 | 755,650 | 35,003 | 39.3 K to 35 K (-10.83 %) |
Oct 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 122.45 | 4,250 | 520,413 | 39,253 | 35 K to 39.3 K (+12.14 %) |
Oct 17 2019 | VRTX | VERTEX PHARMACEUTI ... | SACHS BRUCE I | Director | Option Exercise | A | 0.00 | 264 | 0 | 11,899 | |
Oct 16 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 90.29 | 2,125 | 191,866 | 6,375 | |
Oct 16 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 175.10 | 100 | 17,510 | 35,003 | 35.1 K to 35 K (-0.28 %) |
Oct 16 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 174.46 | 1,136 | 198,187 | 35,103 | 36.2 K to 35.1 K (-3.13 %) |
Oct 16 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 173.44 | 889 | 154,188 | 36,239 | 37.1 K to 36.2 K (-2.39 %) |
Oct 16 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 90.29 | 2,125 | 191,866 | 37,128 | 35 K to 37.1 K (+6.07 %) |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Option Exercise | M | 126.68 | 5,818 | 737,024 | 8,729 | |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Option Exercise | M | 125.71 | 1,270 | 159,652 | 1,907 | |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Sell | S | 167.88 | 1,232 | 206,828 | 5,249 | 6.5 K to 5.2 K (-19.01 %) |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Sell | S | 166.82 | 5,187 | 865,295 | 6,481 | 11.7 K to 6.5 K (-44.45 %) |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Sell | S | 166.08 | 1,960 | 325,517 | 11,668 | 13.6 K to 11.7 K (-14.38 %) |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Buy | M | 126.68 | 5,818 | 737,024 | 13,628 | 7.8 K to 13.6 K (+74.49 %) |
Oct 04 2019 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Buy | M | 125.71 | 1,270 | 159,652 | 7,810 | 6.5 K to 7.8 K (+19.42 %) |
Oct 03 2019 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | SVP, CRO | Sell | S | 167.69 | 444 | 74,454 | 7,252 | 7.7 K to 7.3 K (-5.77 %) |
Oct 03 2019 | VRTX | VERTEX PHARMACEUTI ... | Tatsis Ourania | SVP, CRO | Sell | S | 169.11 | 188 | 31,793 | 7,696 | 7.9 K to 7.7 K (-2.38 %) |